Drug Profile
Research programme: neurological disorder therapeutics - XWPharma
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator XW labs
- Developer XWPharma
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Neurological-disorders in China
- 17 Sep 2020 XW Laboratories is now called XWPharma
- 02 Feb 2018 XW Laboratories plans a phase I trial for Hypersomnia (In volunteers) in Australia , (ACTRN12618000127202)